Jefferies analyst Eun Yang downgraded Biomea Fusion to Hold from Buy.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMEA:
- Jefferies Reconsiders, BMEA Plummets after Sour Diabetes Drug Data
- Biomea Soars on Promising Phase 2 Data in Type 2 Diabetes
- Biomea Fusion price target raised to $45 from $40 at Piper Sandler
- 3 Best Stocks to Buy Now, 6/26/2023, According to Top Analysts
- JPMorgan ups Biomea Fusion target, adds to Analyst Focus List